SrasV1, PascalFrancis, Curation, bibRecord, 000982

Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture

Identifieur interne : 000982 ( PascalFrancis/Curation ); précédent : 000981; suivant : 000983

Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture

Auteurs : Adriaan H. De Wilde [Pays-Bas] ; Dirk Jochmans [Belgique] ; Clara C. Posthuma [Pays-Bas] ; Jessika C. Zevenhoven-Dobbe [Pays-Bas] ; Stefan Van Nieuwkoop [Pays-Bas] ; Theo M. Bestebroer [Pays-Bas] ; Bernadette G. Van Den Hoogen [Pays-Bas] ; Johan Neyts [Belgique] ; Eric J. Snijder [Pays-Bas]

Source :

Antimicrobial agents and chemotherapy [ 0066-4804 ] ; 2014.

RBID : Pascal:14-0220020

Descripteurs français

Pascal (Inist)
- Criblage, Dépistage, Food and Drug Administration, Bibliothèque, Identification, Molécule petite, Inhibiteur, Coronavirus, Réplication, In vitro, Culture cellulaire, Syndrome respiratoire du Moyen-Orient.
Wicri :
- topic : Bibliothèque.

English descriptors

KwdEn :
- Cell culture, Coronavirus, Food and Drug Administration, Identification, In vitro, Inhibitor, Library, Medical screening, Middle East respiratory syndrome, Replication, Screening, Small molecule.

Abstract

Coronaviruses can cause respiratory and enteric disease in a wide variety of human and animal hosts. The 2003 outbreak of severe acute respiratory syndrome (SARS) first demonstrated the potentially lethal consequences of zoonotic coronavirus infections in humans. In 2012, a similar previously unknown coronavirus emerged, Middle East respiratory syndrome coronavirus (MERS-CoV), thus far causing over 650 laboratory-confirmed infections, with an unexplained steep rise in the number of cases being recorded over recent months. The human MERS fatality rate of ˜30% is alarmingly high, even though many deaths were associated with underlying medical conditions. Registered therapeutics for the treatment of coronavirus infections are not available. Moreover, the pace of drug development and registration for human use is generally incompatible with strategies to combat emerging infectious diseases. Therefore, we have screened a library of 348 FDA-approved drugs for anti-MERS-CoV activity in cell culture. If such compounds proved sufficiently potent, their efficacy might be directly assessed in MERS patients. We identified four compounds (chloroquine, chlorpromazine, loperamide, and lopinavir) inhibiting MERS-CoV replication in the low-micromolar range (50% effective concentrations [EC₅₀s], 3 to 8 μM). Moreover, these compounds also inhibit the replication of SARS coronavirus and human coronavirus 229E. Although their protective activity (alone or in combination) remains to be assessed in animal models, our findings may offer a starting point for treatment of patients infected with zoonotic coronaviruses like MERS-CoV. Although they may not necessarily reduce viral replication to very low levels, a moderate viral load reduction may create a window during which to mount a protective immune response.

A01	`01`	`1`		`@0 0066-4804`
A02	`01`			`@0 AACHAX`
A03		`1`		`@0 Antimicrob. agents chemother.`
A05				`@2 58`
A06				`@2 8`
A08	`01`	`1`	`ENG`	`@1 Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture`
A11	`01`	`1`		`@1 DE WILDE (Adriaan H.)`
A11	`02`	`1`		`@1 JOCHMANS (Dirk)`
A11	`03`	`1`		`@1 POSTHUMA (Clara C.)`
A11	`04`	`1`		`@1 ZEVENHOVEN-DOBBE (Jessika C.)`
A11	`05`	`1`		`@1 VAN NIEUWKOOP (Stefan)`
A11	`06`	`1`		`@1 BESTEBROER (Theo M.)`
A11	`07`	`1`		`@1 VAN DEN HOOGEN (Bernadette G.)`
A11	`08`	`1`		`@1 NEYTS (Johan)`
A11	`09`	`1`		`@1 SNIJDER (Eric J.)`
A14	`01`			`@1 Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center @2 Leiden @3 NLD @Z 1 aut. @Z 3 aut. @Z 4 aut. @Z 9 aut.`
A14	`02`			`@1 Rega Institute for Medical Research, KU @2 Leuven @3 BEL @Z 2 aut. @Z 8 aut.`
A14	`03`			`@1 Department of Viroscience, Erasmus Medical Center @2 Rotterdam @3 NLD @Z 5 aut. @Z 6 aut. @Z 7 aut.`
A20				`@1 4875-4884`
A21				`@1 2014`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 13334 @5 354000504837190730`
A44				`@0 0000 @1 © 2014 INIST-CNRS. All rights reserved.`
A45				`@0 85 ref.`
A47	`01`	`1`		`@0 14-0220020`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Antimicrobial agents and chemotherapy`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Coronaviruses can cause respiratory and enteric disease in a wide variety of human and animal hosts. The 2003 outbreak of severe acute respiratory syndrome (SARS) first demonstrated the potentially lethal consequences of zoonotic coronavirus infections in humans. In 2012, a similar previously unknown coronavirus emerged, Middle East respiratory syndrome coronavirus (MERS-CoV), thus far causing over 650 laboratory-confirmed infections, with an unexplained steep rise in the number of cases being recorded over recent months. The human MERS fatality rate of ˜30% is alarmingly high, even though many deaths were associated with underlying medical conditions. Registered therapeutics for the treatment of coronavirus infections are not available. Moreover, the pace of drug development and registration for human use is generally incompatible with strategies to combat emerging infectious diseases. Therefore, we have screened a library of 348 FDA-approved drugs for anti-MERS-CoV activity in cell culture. If such compounds proved sufficiently potent, their efficacy might be directly assessed in MERS patients. We identified four compounds (chloroquine, chlorpromazine, loperamide, and lopinavir) inhibiting MERS-CoV replication in the low-micromolar range (50% effective concentrations [EC₅₀s], 3 to 8 μM). Moreover, these compounds also inhibit the replication of SARS coronavirus and human coronavirus 229E. Although their protective activity (alone or in combination) remains to be assessed in animal models, our findings may offer a starting point for treatment of patients infected with zoonotic coronaviruses like MERS-CoV. Although they may not necessarily reduce viral replication to very low levels, a moderate viral load reduction may create a window during which to mount a protective immune response.
C02	`01`	`X`		`@0 002B02S`
C02	`02`	`X`		`@0 002B05C02C`
C03	`01`	`X`	`FRE`	`@0 Criblage @5 01`
C03	`01`	`X`	`ENG`	`@0 Screening @5 01`
C03	`01`	`X`	`SPA`	`@0 Cernido @5 01`
C03	`02`	`X`	`FRE`	`@0 Dépistage @5 02`
C03	`02`	`X`	`ENG`	`@0 Medical screening @5 02`
C03	`02`	`X`	`SPA`	`@0 Descubrimiento @5 02`
C03	`03`	`X`	`FRE`	`@0 Food and Drug Administration @5 03`
C03	`03`	`X`	`ENG`	`@0 Food and Drug Administration @5 03`
C03	`03`	`X`	`SPA`	`@0 Food and Drug Administration @5 03`
C03	`04`	`X`	`FRE`	`@0 Bibliothèque @5 04`
C03	`04`	`X`	`ENG`	`@0 Library @5 04`
C03	`04`	`X`	`SPA`	`@0 Biblioteca @5 04`
C03	`05`	`X`	`FRE`	`@0 Identification @5 05`
C03	`05`	`X`	`ENG`	`@0 Identification @5 05`
C03	`05`	`X`	`SPA`	`@0 Identificación @5 05`
C03	`06`	`X`	`FRE`	`@0 Molécule petite @5 06`
C03	`06`	`X`	`ENG`	`@0 Small molecule @5 06`
C03	`06`	`X`	`SPA`	`@0 Molécula pequeña @5 06`
C03	`07`	`X`	`FRE`	`@0 Inhibiteur @5 07`
C03	`07`	`X`	`ENG`	`@0 Inhibitor @5 07`
C03	`07`	`X`	`SPA`	`@0 Inhibidor @5 07`
C03	`08`	`X`	`FRE`	`@0 Coronavirus @2 NW @5 08`
C03	`08`	`X`	`ENG`	`@0 Coronavirus @2 NW @5 08`
C03	`08`	`X`	`SPA`	`@0 Coronavirus @2 NW @5 08`
C03	`09`	`X`	`FRE`	`@0 Réplication @5 09`
C03	`09`	`X`	`ENG`	`@0 Replication @5 09`
C03	`09`	`X`	`SPA`	`@0 Replicación @5 09`
C03	`10`	`X`	`FRE`	`@0 In vitro @5 10`
C03	`10`	`X`	`ENG`	`@0 In vitro @5 10`
C03	`10`	`X`	`SPA`	`@0 In vitro @5 10`
C03	`11`	`X`	`FRE`	`@0 Culture cellulaire @5 11`
C03	`11`	`X`	`ENG`	`@0 Cell culture @5 11`
C03	`11`	`X`	`SPA`	`@0 Cultivo celular @5 11`
C03	`12`	`X`	`FRE`	`@0 Syndrome respiratoire du Moyen-Orient @4 CD @5 96`
C03	`12`	`X`	`ENG`	`@0 Middle East respiratory syndrome @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`01`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`01`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`02`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`02`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`03`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`03`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`04`	`X`	`FRE`	`@0 Pathologie de l'appareil respiratoire @5 37`
C07	`04`	`X`	`ENG`	`@0 Respiratory disease @5 37`
C07	`04`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 37`
C07	`05`	`X`	`FRE`	`@0 Virose @5 38`
C07	`05`	`X`	`ENG`	`@0 Viral disease @5 38`
C07	`05`	`X`	`SPA`	`@0 Virosis @5 38`
C07	`06`	`X`	`FRE`	`@0 Infection`
C07	`06`	`X`	`ENG`	`@0 Infection`
C07	`06`	`X`	`SPA`	`@0 Infección`
N21				`@1 265`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000005

Links to Exploration step

Pascal:14-0220020

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture</title>
<author><name sortKey="De Wilde, Adriaan H" sort="De Wilde, Adriaan H" uniqKey="De Wilde A" first="Adriaan H." last="De Wilde">Adriaan H. De Wilde</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Jochmans, Dirk" sort="Jochmans, Dirk" uniqKey="Jochmans D" first="Dirk" last="Jochmans">Dirk Jochmans</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Rega Institute for Medical Research, KU</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Posthuma, Clara C" sort="Posthuma, Clara C" uniqKey="Posthuma C" first="Clara C." last="Posthuma">Clara C. Posthuma</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Zevenhoven Dobbe, Jessika C" sort="Zevenhoven Dobbe, Jessika C" uniqKey="Zevenhoven Dobbe J" first="Jessika C." last="Zevenhoven-Dobbe">Jessika C. Zevenhoven-Dobbe</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Van Nieuwkoop, Stefan" sort="Van Nieuwkoop, Stefan" uniqKey="Van Nieuwkoop S" first="Stefan" last="Van Nieuwkoop">Stefan Van Nieuwkoop</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Viroscience, Erasmus Medical Center</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Bestebroer, Theo M" sort="Bestebroer, Theo M" uniqKey="Bestebroer T" first="Theo M." last="Bestebroer">Theo M. Bestebroer</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Viroscience, Erasmus Medical Center</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Van Den Hoogen, Bernadette G" sort="Van Den Hoogen, Bernadette G" uniqKey="Van Den Hoogen B" first="Bernadette G." last="Van Den Hoogen">Bernadette G. Van Den Hoogen</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Viroscience, Erasmus Medical Center</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Neyts, Johan" sort="Neyts, Johan" uniqKey="Neyts J" first="Johan" last="Neyts">Johan Neyts</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Rega Institute for Medical Research, KU</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Snijder, Eric J" sort="Snijder, Eric J" uniqKey="Snijder E" first="Eric J." last="Snijder">Eric J. Snijder</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0220020</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0220020 INIST</idno>
<idno type="RBID">Pascal:14-0220020</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000005</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000982</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture</title>
<author><name sortKey="De Wilde, Adriaan H" sort="De Wilde, Adriaan H" uniqKey="De Wilde A" first="Adriaan H." last="De Wilde">Adriaan H. De Wilde</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Jochmans, Dirk" sort="Jochmans, Dirk" uniqKey="Jochmans D" first="Dirk" last="Jochmans">Dirk Jochmans</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Rega Institute for Medical Research, KU</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Posthuma, Clara C" sort="Posthuma, Clara C" uniqKey="Posthuma C" first="Clara C." last="Posthuma">Clara C. Posthuma</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Zevenhoven Dobbe, Jessika C" sort="Zevenhoven Dobbe, Jessika C" uniqKey="Zevenhoven Dobbe J" first="Jessika C." last="Zevenhoven-Dobbe">Jessika C. Zevenhoven-Dobbe</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Van Nieuwkoop, Stefan" sort="Van Nieuwkoop, Stefan" uniqKey="Van Nieuwkoop S" first="Stefan" last="Van Nieuwkoop">Stefan Van Nieuwkoop</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Viroscience, Erasmus Medical Center</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Bestebroer, Theo M" sort="Bestebroer, Theo M" uniqKey="Bestebroer T" first="Theo M." last="Bestebroer">Theo M. Bestebroer</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Viroscience, Erasmus Medical Center</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Van Den Hoogen, Bernadette G" sort="Van Den Hoogen, Bernadette G" uniqKey="Van Den Hoogen B" first="Bernadette G." last="Van Den Hoogen">Bernadette G. Van Den Hoogen</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Viroscience, Erasmus Medical Center</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Neyts, Johan" sort="Neyts, Johan" uniqKey="Neyts J" first="Johan" last="Neyts">Johan Neyts</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Rega Institute for Medical Research, KU</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Snijder, Eric J" sort="Snijder, Eric J" uniqKey="Snijder E" first="Eric J." last="Snijder">Eric J. Snijder</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Antimicrobial agents and chemotherapy</title>
<title level="j" type="abbreviated">Antimicrob. agents chemother.</title>
<idno type="ISSN">0066-4804</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Antimicrobial agents and chemotherapy</title>
<title level="j" type="abbreviated">Antimicrob. agents chemother.</title>
<idno type="ISSN">0066-4804</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cell culture</term>
<term>Coronavirus</term>
<term>Food and Drug Administration</term>
<term>Identification</term>
<term>In vitro</term>
<term>Inhibitor</term>
<term>Library</term>
<term>Medical screening</term>
<term>Middle East respiratory syndrome</term>
<term>Replication</term>
<term>Screening</term>
<term>Small molecule</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Criblage</term>
<term>Dépistage</term>
<term>Food and Drug Administration</term>
<term>Bibliothèque</term>
<term>Identification</term>
<term>Molécule petite</term>
<term>Inhibiteur</term>
<term>Coronavirus</term>
<term>Réplication</term>
<term>In vitro</term>
<term>Culture cellulaire</term>
<term>Syndrome respiratoire du Moyen-Orient</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Bibliothèque</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Coronaviruses can cause respiratory and enteric disease in a wide variety of human and animal hosts. The 2003 outbreak of severe acute respiratory syndrome (SARS) first demonstrated the potentially lethal consequences of zoonotic coronavirus infections in humans. In 2012, a similar previously unknown coronavirus emerged, Middle East respiratory syndrome coronavirus (MERS-CoV), thus far causing over 650 laboratory-confirmed infections, with an unexplained steep rise in the number of cases being recorded over recent months. The human MERS fatality rate of ˜30% is alarmingly high, even though many deaths were associated with underlying medical conditions. Registered therapeutics for the treatment of coronavirus infections are not available. Moreover, the pace of drug development and registration for human use is generally incompatible with strategies to combat emerging infectious diseases. Therefore, we have screened a library of 348 FDA-approved drugs for anti-MERS-CoV activity in cell culture. If such compounds proved sufficiently potent, their efficacy might be directly assessed in MERS patients. We identified four compounds (chloroquine, chlorpromazine, loperamide, and lopinavir) inhibiting MERS-CoV replication in the low-micromolar range (50% effective concentrations [EC<sub>50</sub>
s], 3 to 8 μM). Moreover, these compounds also inhibit the replication of SARS coronavirus and human coronavirus 229E. Although their protective activity (alone or in combination) remains to be assessed in animal models, our findings may offer a starting point for treatment of patients infected with zoonotic coronaviruses like MERS-CoV. Although they may not necessarily reduce viral replication to very low levels, a moderate viral load reduction may create a window during which to mount a protective immune response.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0066-4804</s0>
</fA01>
<fA02 i1="01"><s0>AACHAX</s0>
</fA02>
<fA03 i2="1"><s0>Antimicrob. agents chemother.</s0>
</fA03>
<fA05><s2>58</s2>
</fA05>
<fA06><s2>8</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>DE WILDE (Adriaan H.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>JOCHMANS (Dirk)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>POSTHUMA (Clara C.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>ZEVENHOVEN-DOBBE (Jessika C.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>VAN NIEUWKOOP (Stefan)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>BESTEBROER (Theo M.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>VAN DEN HOOGEN (Bernadette G.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>NEYTS (Johan)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>SNIJDER (Eric J.)</s1>
</fA11>
<fA14 i1="01"><s1>Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Rega Institute for Medical Research, KU</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Viroscience, Erasmus Medical Center</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>4875-4884</s1>
</fA20>
<fA21><s1>2014</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>13334</s2>
<s5>354000504837190730</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>85 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>14-0220020</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Antimicrobial agents and chemotherapy</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Coronaviruses can cause respiratory and enteric disease in a wide variety of human and animal hosts. The 2003 outbreak of severe acute respiratory syndrome (SARS) first demonstrated the potentially lethal consequences of zoonotic coronavirus infections in humans. In 2012, a similar previously unknown coronavirus emerged, Middle East respiratory syndrome coronavirus (MERS-CoV), thus far causing over 650 laboratory-confirmed infections, with an unexplained steep rise in the number of cases being recorded over recent months. The human MERS fatality rate of ˜30% is alarmingly high, even though many deaths were associated with underlying medical conditions. Registered therapeutics for the treatment of coronavirus infections are not available. Moreover, the pace of drug development and registration for human use is generally incompatible with strategies to combat emerging infectious diseases. Therefore, we have screened a library of 348 FDA-approved drugs for anti-MERS-CoV activity in cell culture. If such compounds proved sufficiently potent, their efficacy might be directly assessed in MERS patients. We identified four compounds (chloroquine, chlorpromazine, loperamide, and lopinavir) inhibiting MERS-CoV replication in the low-micromolar range (50% effective concentrations [EC<sub>50</sub>
s], 3 to 8 μM). Moreover, these compounds also inhibit the replication of SARS coronavirus and human coronavirus 229E. Although their protective activity (alone or in combination) remains to be assessed in animal models, our findings may offer a starting point for treatment of patients infected with zoonotic coronaviruses like MERS-CoV. Although they may not necessarily reduce viral replication to very low levels, a moderate viral load reduction may create a window during which to mount a protective immune response.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Criblage</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Screening</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Cernido</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Dépistage</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Medical screening</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Descubrimiento</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Food and Drug Administration</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Food and Drug Administration</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Food and Drug Administration</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Bibliothèque</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Library</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Biblioteca</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Identification</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Identification</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Identificación</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Molécule petite</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Small molecule</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Molécula pequeña</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Inhibiteur</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Inhibitor</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Inhibidor</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Réplication</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Replication</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Replicación</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>In vitro</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>In vitro</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>In vitro</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Culture cellulaire</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Cell culture</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Cultivo celular</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Syndrome respiratoire du Moyen-Orient</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Middle East respiratory syndrome</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie de l'appareil respiratoire</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Virose</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Viral disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Virosis</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fN21><s1>265</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000982 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000982 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:14-0220020
   |texte=   Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture

Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri